CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

GSK is funding public health organizations working to address US adult immunization gaps and increase community vaccine education, outreach and access These grants are part of GSK’s COiMMUNITY ...

GSK plc (LSE ... awarding nearly $2 million to 15 regional, state and national non-profits and community-based groups working to boost adult immunization through improved vaccine education ...

Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world. In the Phase 2 study S4V02 (Identifier: NCT06523231), the safety and ...

Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world. In the Phase 2 study S4V02 (Identifier: NCT06523231), the safety and ...

ATLANTA — Georgia public health leaders on Tuesday underscored the gravity of the Texas measles outbreak, and expressed concern over the impact of misinformation from Washington. Three ...

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing respiratory syncytial virus (RSV) vaccines, according to a filing made in Delaware ...

FILE - Staff Sgt. Travis Snyder, left, receives the first dose of the Pfizer COVID-19 vaccine given at Madigan Army Medical Center at Joint Base Lewis-McChord in Washington state, Dec. 16 ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

The MMR Vaccine treats measles, mumps and rubella, and is available starting at a child's first birthday and the second dose at fourth birthday. "As long as the child is over three years old ...